FTC tar­gets more drug patents, go­ing af­ter obe­si­ty, di­a­betes and asth­ma med­ica­tions

An­titrust reg­u­la­tors at the Fed­er­al Trade Com­mis­sion ex­pand­ed their cam­paign on what they call “junk” patents, send­ing a new round of warn­ing let­ters to drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER